Basic Information
RNALocate ID: | RLID:01001300 |
RNA Symbol: | hsa-miR-20a-5p |
Localization: | Mitochondrion |
RNA Information
RNA Name: | hsa-miR-20a |
RNA ID: | miRBase:MIMAT0000075 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21637849 |
Tissue/Cell Line: | Skeletal muscle myoblasts |
Method: | ISH|qRT-PCR |
Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001294 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001295 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001296 | Cytoplasm | HeLa cells | 23940654 |
RLID:01001297 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001298 | Mitochondrion | Myotube | 27396686 |
RLID:01001299 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001301 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001302 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001303 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01001304 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000737 | Exosome | Sera | 24978137 |
RLID:11000738 | Exosome | Human cervical carcinoma cell line (HeLa|SiHa) | 25760330 |
RLID:11000739 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000740 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000741 | Exosome | Breast milk | 22211110 |
RLID:11000742 | Exosome | Brain tissue | 23382797 |
RLID:11000743 | Exosome | Plasma | 23663360 |
RLID:11000744 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000745 | Exosome | Serum | 25349172 |
RLID:11000746 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000747 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000748 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000749 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000750 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000751 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000012 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Endothelial cells|Epithelial cells|Lymphoma tissue|Tongue tissue | |
RLID-D:11000274 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-20a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-27697 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-27698 |
MNDR | hsa-miR-20a-5p | Colorectal adenocarcinoma | MNDR-E-MI-27699 |
MNDR | hsa-miR-20a-5p | Oral squamous cell carcinoma | MNDR-E-MI-27700 |
MNDR | hsa-miR-20a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-27701 |
MNDR | hsa-miR-20a-5p | Medulloblastoma | MNDR-E-MI-27702 |
MNDR | hsa-miR-20a-5p | B cell lymphoma of malt type | MNDR-E-MI-27703 |
MNDR | hsa-miR-20a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27704 |
MNDR | hsa-miR-20a-5p | Autism spectrum disorder | MNDR-E-MI-27705 |
MNDR | hsa-miR-20a-5p | Lymphoma | MNDR-E-MI-27706 |
MNDR | hsa-miR-20a-5p | Lymphoma non-hodgkin | MNDR-E-MI-27707 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27708 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27709 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27710 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27711 |
MNDR | hsa-miR-20a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27712 |
MNDR | hsa-miR-20a-5p | Breast cancer luminal | MNDR-E-MI-27713 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease type c | MNDR-E-MI-27714 |
MNDR | hsa-miR-20a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-27715 |
MNDR | hsa-miR-20a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-27716 |
MNDR | hsa-miR-20a-5p | Dermatomyositis | MNDR-E-MI-27717 |
MNDR | hsa-miR-20a-5p | Prostate cancer | MNDR-E-MI-27718 |
MNDR | hsa-miR-20a-5p | Gastric cancer | MNDR-E-MI-27719 |
MNDR | hsa-miR-20a-5p | Gastric lymphoma | MNDR-E-MI-27720 |
MNDR | hsa-miR-20a-5p | Alzheimer disease | MNDR-E-MI-27721 |
MNDR | hsa-miR-20a-5p | Intracranial aneurysm | MNDR-E-MI-27722 |
MNDR | hsa-miR-20a-5p | Bladder cancer | MNDR-E-MI-27723 |
MNDR | hsa-miR-20a-5p | Esophageal carcinoma | MNDR-E-MI-27724 |
MNDR | hsa-miR-20a-5p | Dysautonomia familial | MNDR-E-MI-27725 |
MNDR | hsa-miR-20a-5p | Primary biliary cirrhosis | MNDR-E-MI-27726 |
MNDR | hsa-miR-20a-5p | Leukemia | MNDR-E-MI-27727 |
MNDR | hsa-miR-20a-5p | Ataxia telangiectasia | MNDR-E-MI-27728 |
MNDR | hsa-miR-20a-5p | Huntington disease | MNDR-E-MI-27729 |
MNDR | hsa-miR-20a-5p | Chorea | MNDR-E-MI-27730 |
MNDR | hsa-miR-20a-5p | Cardiovascular disease | MNDR-E-MI-27731 |
MNDR | hsa-miR-20a-5p | Carotid stenosis | MNDR-E-MI-27732 |
MNDR | hsa-miR-20a-5p | Moyamoya disease | MNDR-E-MI-27733 |
MNDR | hsa-miR-20a-5p | Lung cancer | MNDR-E-MI-27734 |
MNDR | hsa-miR-20a-5p | Down syndrome | MNDR-E-MI-27735 |
MNDR | hsa-miR-20a-5p | Parkinson disease | MNDR-E-MI-27736 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease | MNDR-E-MI-27737 |
MNDR | hsa-miR-20a-5p | Colon carcinoma | MNDR-E-MI-27738 |
MNDR | hsa-miR-20a-5p | Basal-like breast cancer | MNDR-E-MI-27739 |
MNDR | hsa-miR-20a-5p | Squamous cell carcinoma | MNDR-E-MI-27740 |
MNDR | hsa-miR-20a-5p | Thyroid cancer | MNDR-E-MI-27741 |
MNDR | hsa-miR-20a-5p | Pituitary neoplasms | MNDR-E-MI-27742 |
MNDR | hsa-miR-20a-5p | Pancreatic cancer | MNDR-E-MI-27743 |
MNDR | hsa-miR-20a-5p | Melanoma | MNDR-E-MI-27744 |
MNDR | hsa-miR-20a-5p | Lesch-nyhan syndrome | MNDR-E-MI-27745 |
MNDR | hsa-miR-20a-5p | Rectum adenocarcinoma | MNDR-E-MI-27746 |
MNDR | hsa-miR-20a-5p | Nephroblastoma | MNDR-E-MI-27747 |
MNDR | hsa-miR-20a-5p | Colon cancer | MNDR-E-MI-27748 |
MNDR | hsa-miR-20a-5p | Ischemic attack transient | MNDR-E-MI-27749 |
MNDR | hsa-miR-20a-5p | Colon adenocarcinoma | MNDR-E-MI-27750 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis | MNDR-E-MI-27751 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27752 |
MNDR | hsa-miR-20a-5p | Ovarian cancer | MNDR-E-MI-27753 |
MNDR | hsa-miR-20a-5p | Prostate adenocarcinoma | MNDR-E-MI-27754 |
MNDR | hsa-miR-20a-5p | Kidney cancer | MNDR-E-MI-27755 |
MNDR | hsa-miR-20a-5p | Endometriosis | MNDR-E-MI-27756 |
MNDR | hsa-miR-20a-5p | Carcinoma ductal breast | MNDR-E-MI-27757 |
MNDR | hsa-miR-20a-5p | Glioblastoma | MNDR-E-MI-27758 |
MNDR | hsa-miR-20a-5p | Astrocytoma | MNDR-E-MI-27759 |
MNDR | hsa-miR-20a-5p | Glioma | MNDR-E-MI-27760 |
MNDR | hsa-miR-20a-5p | Oligodendroglioma | MNDR-E-MI-27761 |
MNDR | hsa-miR-20a-5p | Central nervous system lymphoma | MNDR-E-MI-27762 |
MNDR | hsa-miR-20a-5p | Chordoma | MNDR-E-MI-27763 |
MNDR | hsa-miR-20a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27764 |
MNDR | hsa-miR-20a-5p | Epilepsy temporal lobe | MNDR-E-MI-27765 |
MNDR | hsa-miR-20a-5p | Osteosarcoma | MNDR-E-MI-27766 |
MNDR | hsa-miR-20a-5p | Liposarcoma | MNDR-E-MI-27767 |
MNDR | hsa-miR-20a-5p | Meningioma | MNDR-E-MI-27768 |
MNDR | hsa-miR-20a-5p | Liver cancer | MNDR-E-MI-27769 |
MNDR | hsa-miR-20a-5p | Uterine cancer | MNDR-E-MI-27770 |
MNDR | hsa-miR-20a-5p | Gastric adenocarcinoma | MNDR-E-MI-27771 |
MNDR | hsa-miR-20a-5p | Pituitary adenoma | MNDR-E-MI-27772 |
MNDR | hsa-miR-20a-5p | Lung squamous cell carcinoma | MNDR-E-MI-27773 |
MNDR | hsa-miR-20a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-27774 |
MNDR | hsa-miR-20a-5p | Lung adenocarcinoma | MNDR-E-MI-27775 |
MNDR | hsa-miR-20a-5p | Adrenocortical carcinoma | MNDR-E-MI-27776 |
MNDR | hsa-miR-20a-5p | Thyroid carcinoma | MNDR-E-MI-27777 |
MNDR | hsa-miR-20a-5p | Ovarian carcinoma | MNDR-E-MI-27778 |
MNDR | hsa-miR-20a-5p | Bladder urothelial carcinoma | MNDR-E-MI-27779 |
MNDR | hsa-miR-20a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-27780 |
MNDR | hsa-miR-20a-5p | Brain stem cancer | MNDR-E-MI-27781 |
MNDR | hsa-miR-20a-5p | Cervical cancer | MNDR-E-MI-27782 |
MNDR | hsa-miR-20a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-27783 |
MNDR | hsa-miR-20a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-27784 |
MNDR | hsa-miR-20a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-27785 |
MNDR | hsa-miR-20a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-27786 |
MNDR | hsa-miR-20a-5p | Biliary tract cancer | MNDR-E-MI-27787 |
MNDR | hsa-miR-20a-5p | Pancreatic carcinoma | MNDR-E-MI-27788 |
MNDR | hsa-miR-20a-5p | Cholangiocarcinoma | MNDR-E-MI-27789 |
MNDR | hsa-miR-20a-5p | Esophageal cancer | MNDR-E-MI-27790 |
MNDR | hsa-miR-20a-5p | Lung small cell carcinoma | MNDR-E-MI-27791 |
MNDR | hsa-miR-20a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-27792 |
MNDR | hsa-miR-20a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-27793 |
MNDR | hsa-miR-20a-5p | Acute t cell leukemia | MNDR-E-MI-27794 |
MNDR | hsa-miR-20a-5p | Pulmonary hypertension | MNDR-E-MI-27795 |
MNDR | hsa-miR-20a-5p | Adenoma | MNDR-E-MI-27796 |
MNDR | hsa-miR-20a-5p | Breast invasive carcinoma | MNDR-E-MI-27797 |
MNDR | hsa-miR-20a-5p | Early hepatocellular carcinoma | MNDR-E-MI-27798 |
MNDR | hsa-miR-20a-5p | B-cell lymphoma | MNDR-E-MI-27799 |
MNDR | hsa-miR-20a-5p | Rheumatoid arthritis | MNDR-E-MI-27800 |
MNDR | hsa-miR-20a-5p | T-cell leukemia | MNDR-E-MI-27801 |
MNDR | hsa-miR-20a-5p | Retinoblastoma | MNDR-E-MI-27802 |
MNDR | hsa-miR-20a-5p | Neuroblastoma | MNDR-E-MI-27803 |
MNDR | hsa-miR-20a-5p | Chronic myeloid leukemia | MNDR-E-MI-27804 |
MNDR | hsa-miR-20a-5p | Hodgkin disease | MNDR-E-MI-27805 |
MNDR | hsa-miR-20a-5p | Burkitt lymphoma | MNDR-E-MI-27806 |
MNDR | hsa-miR-20a-5p | Lymphosarcoma | MNDR-E-MI-27807 |
MNDR | hsa-miR-20a-5p | Neuromyelitis optica | MNDR-E-MI-27808 |
MNDR | hsa-miR-20a-5p | Psoriasis | MNDR-E-MI-27809 |
MNDR | hsa-miR-20a-5p | Acute myelogenous leukemia | MNDR-E-MI-27810 |
MNDR | hsa-miR-20a-5p | Colorectal cancer | MNDR-E-MI-27811 |
MNDR | hsa-miR-20a-5p | Multiple myeloma | MNDR-E-MI-27812 |
MNDR | hsa-miR-20a-5p | Acute lymphocytic leukemia | MNDR-E-MI-27813 |
MNDR | hsa-miR-20a-5p | Uterine cervical neoplasms | MNDR-E-MI-27814 |
MNDR | hsa-miR-20a-5p | Ependymoma | MNDR-E-MI-27815 |
MNDR | hsa-miR-20a-5p | Nasopharyngeal cancer | MNDR-E-MI-27816 |
MNDR | hsa-miR-20a-5p | Prostatic neoplasms | MNDR-E-MI-27817 |
MNDR | hsa-miR-20a-5p | Pseudorabies | MNDR-E-MI-27818 |
MNDR | hsa-miR-20a-5p | Arsenic poisoning | MNDR-E-MI-27819 |
MNDR | hsa-miR-20a-5p | Stroke lacunar | MNDR-E-MI-27820 |
MNDR | hsa-miR-20a-5p | Duke C | MNDR-E-MI-27821 |
MNDR | hsa-miR-20a-5p | High grade dysplastic nodule | MNDR-E-MI-27822 |
MNDR | hsa-miR-20a-5p | Tubulovillous adenoma | MNDR-E-MI-27823 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABL2 | Homo sapiens | RR00027165 |
TOP